Discovery of high-affinity peptide ligands for vancomycin

Nianhuan Yao1, Chun-Yi Wu, Wenwu Xiao

  • 1Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Cancer Center, University of California, Davis, Sacramento, CA 95817, USA.

Biopolymers
|February 9, 2008
PubMed

Insights

Researchers developed novel "OBOC inverted" peptide libraries to discover vancomycin ligands. They identified peptidomimetics with significantly higher binding affinity than the natural Kaa target, improving vancomycin

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Drug Discovery

Background:

  • Vancomycin is a critical antibiotic for Gram-positive bacteria, including MRSA.
  • Its antibacterial action relies on binding the Lys-D-Ala-D-Ala (Kaa) motif of bacterial cell wall precursors.
  • A free carboxyl group on the terminal D-Ala of Kaa is essential for vancomycin binding.

Purpose of the Study:

  • To develop a novel synthetic strategy for one-bead-one-compound (OBOC) peptide libraries with free carboxyl ends.
  • To discover novel Kaa-based peptide ligands that bind vancomycin with higher affinity.
  • To optimize lead compounds through focused peptidomimetic libraries.

Main Methods:

  • Development of "OBOC inverted" combinatorial peptide libraries with free D-Ala-D-Ala carboxyl termini.
  • Screening of these libraries against vancomycin to identify binding ligands.
  • Design, synthesis, and screening of focused peptidomimetic libraries for enhanced affinity.

Main Results:

  • Identification of novel peptide ligands that bind vancomycin.
  • Discovery of peptidomimetic ligands exhibiting higher binding affinity than Kaa.
  • A lead peptidomimetic ligand demonstrated a 50-fold increase in binding affinity (K(D) = 1.03 µM) compared to Kaa (K(D) = 50 µM).

Conclusions:

  • The "OBOC inverted" library approach is effective for discovering high-affinity vancomycin ligands.
  • Optimized peptidomimetics show potential for improved vancomycin-based therapeutics.
  • This strategy advances the development of novel antibiotics targeting resistant bacteria.